Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative joint disease. The Clinical management of TMJ-OA is largely palliative and anti-inflammatory drugs; analgesics and lubricating supplements are primarily used for the treatment of TMJ-OA. Thus, agents which modify both the cartilage and subchondral bone are promising for TMJ-OA, including parathyroid hormone (PTH) and alendronate. This presentation will discuss the individual and synergistic effects of PTH and alendronate on the osteochondral tissue of TMJ.
Learning Objectives:
After this lecture, attendees will be able to:
To discuss the effects of intermittent-PTH and alendronate treatment on the microarchitecture of the cartilage and the subchondral bone of the TMJ.
To evaluate the effects of independent and simultaneous treatment with intermittent-PTH and alendronate on TMJ.
